Preliminary Program: Sunday
 May 18

7:30 a.m.-5 p.m.

Registration/Course Enrollment Open

8 a.m.-11 a.m.

Industry-Supported Symposia

IS9. Diagnosis and Treatment: Mood Stabilizers Across the Psychiatric SpectrumSupported by Abbott Laboratories

    A. A Systematic Approach to the Treatment of Impulsivity Alan C. Swann, M.D.

    B. The Role of Mood Stabilizers in the Management of Agitation in Dementia J. Michael Ryan, M.D.

    C. Efficacy of Treatment With Mood Stabilizers in Acute Schizophrenia Carol A. Tamminga, M.D.

    D. Comorbidities and Treatment Issues in Substance Use Disorders Hugh Myrick, M.D.

    E. Affective Instability and Impulsive Aggression in Cluster B and Developmental Disorders Eric Hollander, M.D.

IS10. Moods, Cycles, and MotherhoodSupported by GlaxoSmithKline

    A. Depression in Pregnancy and Lactation: Making Informed Decisions to Protect the Mother and Infant Zachary N. Stowe, M.D.

    B. Mothers, Babies, and Children: Mental Health in the Postpartum and Beyond Shaila Misri, M.D.

    C. Pharmacological Treatment of Premenstrual Dysphoria: What Is Sufficient? Kimberly A. Yonkers, M.D.

    D. Is It Just Me or Is It Hot in Here? What Every Psychiatrist Should Know About Menopause C. Neill Epperson, M.D.

IS11. Enhancing Skill Treating Comorbid Depression and Neurological IllnessSupported by Organon Inc.

    A. Depression in Neurological Disorders Gary J. Tucker , M.D.

    B. Depression in Dementing Disorders Jeffrey L. Cummings, M.D.

    C. Depression Following Traumatic Brain Injury David B. Arciniegas, M.D.

    D. Treatment of Depression in Patients With Life-Threatening and Terminal Illness Norman Sussman, M.D.

    E. Targeting Antidepressant Therapy to Medical Comorbidity Steven L. Dubovsky, M.D.

IS12. An Integrated Approach to the Management of Bipolar Disorder: An Alliance of Science and MedicineSupported by Eli Lilly and Company

    A. The Role of Genetics in Bipolar Disease Wade H. Berrettini, M.D.

    B. The Importance of Mood Stabilization in the Treatment of Mania John Cookson, M.B.

    C. Bipolar Depression and Substance Abuse: Which Is the Driving Force? Joseph F. Goldberg, M.D.

    D. A Disease Management Strategy for Bipolar Disorder Ellen Frank, Ph.D.

    E. Optimizing Treatment to Prevent Relapse Paul E. Keck Jr., M.D.

IS13. Remission in Psychiatric Disorders: Definitions, Issues, and TreatmentsSupported by Wyeth Pharmaceuticals

    A. Psychosocial Functioning in Depression Ivan W. Miller, Ph.D.

    B. Remission in Major Depression: A Frequently Illusive Goal Alan F. Schatzberg, M.D.

    C. Response and Remission in GAD Alan J. Gelenberg, M.D.

    D. Remission in Bipolar Disorder Across the Life Span Kiki D. Chang, M.D.

    E. Response and Remission in Depression: The ACNP Consensus Report John A. Rush, M.D.

8 a.m.-Noon

CME Courses 13-20

8 a.m.-4:30 p.m.

APA Resource Center Open

9 a.m.-4 p.m.

CME Courses 21-27

11 a.m.-4:30 p.m.

Exhibits Open

Publishers’ Bookfair Open

12:30 p.m.-1:30 p.m.

Business Meeting and Forum (Voting Members Only)

1 p.m.-4:30 p.m.

CME Courses 28-34

1:30 p.m.-4:30 p.m.

Industry-Supported Symposia

IS14. Barriers to Optimal Outcome in Anxiety and DepressionSupported by GlaxoSmithKline

    A. From Medication Noncompliance to Medication Interest: The Art of Discussing Medications With Patients Shawn C. Shea, M.D.

    B. Controlled-Release Antidepressant Formulations: Advantages and Limitations David V. Sheehan, M.D.

    C. An Evidence-Based Approach to Clinical Trials in Anxiety and Depression Flavio Kapczinski, Ph.D.

    D. Case-Based Approach to Optimal Outcome in Depression and Anxiety Lori Calabrese, M.D.

IS15. New Challenges in the Management of Depression Supported by Forest Laboratories Inc.

    A. Solving the Conundrum of Childhood Depression Karen D. Wagner, M.D.

    B. Achieving Rapid-Onset of Action and Remission in Depressed Adults Robert M.A. Hirschfeld, M.D.

    C. Tickling the Brain: Advances in Antidepressant Brain Stimulation Techniques Mark S. George, M.D.

    D. Enhancing Collaboration Between the Primary Care Physician and the Psychiatrist Larry Culpepper, M.D.

    E. Maintaining Quality of Life in the Elderly Steven P. Roose, M.D.

IS16. Issues in Treating Mania: Acute and Continuation PhaseSupported by AstraZeneca Pharmaceuticals

    A. Managing Acute Mania in the Emergency Room Michael H. Allen, M.D.

    B. Pharmacological Options for the Treatment of Pediatric Mania Melissa P. DelBello, M.D.

    C. Approaches to the Treatment of Mania Roy H. Perlis, M.D.

    D. Family Intervention and Pharmacotherapy in the Post-Episode Phase of Bipolar Disorder David J. Miklowitz, Ph.D.

    E. Identifying Suicidal Behavioral and At-Risk Patients Gary S. Sachs, M.D.

IS17. Tricks of the Trade in the Long-Term Treatment of DepressionSupported by Organon Inc.

    A. Clinical Management of Psychiatric Comorbidities R. Bruce Lydiard, M.D.

    B. Sexual Dysfunction in Depression Anita L.H. Clayton, M.D.

    C. Sleep Changes During Long-Term Treatment With Antidepressants Maurizio Fava, M.D.

    D. Antidepressant-Induced Cognitive Changes and Apathy: Are There Any Antidotes? Jerrold F. Rosenbaum, M.D.

    E. Practical Approaches to Antidepressant-Induced Weight Gain David L. Ginsberg, M.D.

IS18. Pharmacological Treatment of Chronic Pain: Comorbidity With Depression and Other Psychotic DisordersSupported by Eli Lilly and Company

    A. Psychiatric and Other Comorbidities Associated With Chronic Pain David Fishbain, M.D.

    B. The Neurobiology of Pain Edward C. Covington Jr., M.D.

    C. Adjuvants as Analgesics: Mechanism-Based Pharmacotherapy in Pain Medicine Rollin Gallagher, M.D.

    D. Depression With Painful Physical Symptoms: Treatment With 5HT/Norepinephrine Antidepressants Michael J. Detke, M.D.

    E. The Use of Opioid Analgesics for Chronic Pain: Controversies and Challenges Steven A. King, M.D.

    F. Adjuvant Analgesics: Efficacy Evidence for the Treatment of Neuropathic Pain David Fishbain, M.D.

IS19. Stress, Psychopathology, and the Brain: Novel Intervention StrategiesSupported by Wyeth Pharmaceuticals

    A. Overview of the Relationship Between Stress, Depression, and Anxiety Christine Heim, Ph.D.

    B. The Potential for Gene Therapy in the Treatment of Stress and Related Disorders Robert Sapolsky, Ph.D.

    C. The Biology of Stress and Vulnerability Michael Meaney, Ph.D.

    D. Novel Pharmacological Strategies to Treat Stress-Related Psychopathology and Medical Illnesses Ned H. Kalin, M.D.

IS20. Depression, Apathy, and Fatigue in Neuropsychiatric Disorders Supported by Cephalon Inc.

    A. Disorders of Motivation: The Third Domain of Psychopathology Robert S. Marin, M.D.

    B. Fatigue and Depression in Cancer and AIDS William Breitbart, M.D.

    C. Apathy in Neuropsychiatric Disorders Jeffrey L. Cummings, M.D.

    D. Depression, Fatigue, and Excessive Daytime Sleepiness in Sleep Disorders Mary B. O’Malley, M.D.

    E. Apathy in Schizophrenia Donald C. Goff, M.D.

2:30 p.m.-4 p.m.

Lecture

    L1. Expert Testimony in the Age of DaubertElissa P. Benedek, M.D., and Diane H. Schetky, M.D., AAPL/APA’s Manfred S. Guttmacher Award Lecture

5 p.m.-6:30 p.m.

Opening Session and Presidential Address

7 p.m.-10 p.m.

Industry-Supported Symposia

IS21. Peptides and Hormones as Targets in Antidepressant TreatmentSupported by Merck U.S. Health

    A. Development of a PET Tracer for Clinical Trials of Substance P Antagonists Richard Hargreaves, Ph.D.

    B. Recent Studies on Substance P Antagonists A. John Rush, M.D.

    C. The Therapeutic Potential of Corticotrophin-Releasing Factor Antagonists Ned H. Kalin, M.D.

    D. Estrogen and Mood Elizabeth A. Young, M.D.

    E. The Role of Antiglucocorticoid Agents in the Treatment of Major Depression Charles DeBattista, M.D.

IS22. A Comprehensive Approach to Managing Bipolar Disorder: Bench to Bedside and BeyondSupported by Ortho-McNeil Pharmaceutical

    A. Neuroplasticity and Cellular Resilience in Bipolar Disorder Husseini K. Manji, M.D.

    B. The Treatment of Acute Mania Mark A. Frye, M.D.

    C. Treatment of Bipolar Disorder With Comorbid Psychiatric or Medical Disorders Susan L. McElroy, M.D.

    D. Management of Suicide Prevention in Bipolar Disorder Patients Maria A. Oquendo, M.D.

    E. Psychotherapy for Bipolar Disorder? Ellen Frank, Ph.D.

IS23. A Rational Algorithm for Selecting Atypicals in Schizophrenia and Bipolar DisordersSupported by AstraZeneca Pharmaceuticals

    A. Efficacy of Atypical Antipsychotics: How Do They Compare? Rajiv Tandon, M.D.

    B. Minimizing Specific Medical Problems by Customizing Antipsychotic Selection Henry A. Nasrallah, M.D.

    C. Serious Medical Morbidity and Atypicals: Defining and Avoiding Thresholds of Risk Diana O. Perkins, M.D.

    D. Bipolar Disorders and Schizophrenia: Similarities and Differences in Susceptibilities to Side Effects Claudia F. Baldassano, M.D.

    E. Efficacy to Effectiveness When Treating Schizophrenia Peter J. Weiden, M.D.

IS24. Psychiatry and Medicine: Common Patients, Different PerspectivesSupported by Pfizer Inc.

    A. The Pathophysiology and Psychopharmacology of Comorbid Cardiovascular Disease and Depression Charles B. Nemeroff, M.D.

    B. Medical Illness and Depression: A Delicate Interplay Between Biology and Brain Dominique L. Musselman, M.D.

    C. Management of Anxiety Disorders in Primary Care: Implications for Psychiatrists Risa B. Weisberg, Ph.D.

    D. Long-Term Treatment of Patients With Anxiety and Depression: Why, When, How? Philip T. Ninan, M.D.

    E. The Successful Intervention: Management of the Patient With Medical Comorbidities Larry Culpepper, M.D.

IS25. Medical Considerations in the Management of Special Patient PopulationsSupported by Eli Lilly and Company

    A. Medical Vulnerability in Schizophrenia Donald C. Goff, M.D.

    B. Medical Considerations in Bipolar Disorder Lauren B. Marangell, M.D.

    C. Medical Concerns in Pharmacotherapy for Complicated Pediatric Bipolar Patients Charles S. Schultz, M.D.

    D. Course and Treatment of Bipolar Illness During Pregnancy, Postpartum, and Lactation Lee S. Cohen, M.D.

    E. Medical Comorbidity and Bipolar Disorders in Old Age: Impact on Diagnosis, Treatment, and Outcome Kenneth I. Shulman, M.D.

IS26. Treatment of Comorbidity in Neuropsychiatric Disorders in Children and AdolescentsSupported by Janssen Pharmaceutica

    A. Child and Adolescent Psychiatric Disorders: Bipolar Disorder as a Model Janet Wozniak, M.D.

    B. Rational Management of Disruptive Behavior Disorders and Comorbidity Jeffrey Newcorn, M.D.

    C. Combined Pharmacotherapy in the Management of Bipolar Disorder Robert L. Findling, M.D.

    D. Recent Advances in the Pharmacotherapy of Pervasive Developmental Disorders Christopher J. McDougle, M.D.

    E. Clinically Relevant Drug-Drug Interactions in Pediatric Psychiatry Michael D. Reed, Pharm.D.

IS27. Reducing Suicidality in Schizophrenia and Bipolar DisorderSupported by Novartis Pharmaceuticals Corporation

    A. Suicidality and Its Management in Schizophrenia and Bipolar Disorder Kay R. Jamison, Ph.D.

    B. A Model for Suicide Assessment Douglas G. Jacobs, M.D.

    C. Reducing Suicidality in Schizophrenia and Schizoaffective Disorder Herbert Y. Meltzer, M.D.

    D. Treatment and Suicide Risks Ross J. Baldessarini, M.D. ▪